Cardiovascular disease
Showing of 3 results
Beyond Traditional Risk Factors: Environmental Drivers of Cardiovascular Disease
Innovations in Research
From GLP-1 to Triple Agonists: Transforming Cardiometabolic Care
Ian Neeland, MD, explains how incretin therapies are improving outcomes in cardiovascular, metabolic, and related conditions, while exploring mechanisms, muscle preservation, and strategies for long-term success.
Community-Based Healthcare Model Shows Great Promise by Using ED as Warning Signal for Cardiovascular Disease
Innovations in Urology | Fall 2025
Results are loading...